Study identification

PURI

https://redirect.ema.europa.eu/resource/36645

EU PAS number

EUPAS34331

Study ID

36645

Official title and acronym

CASE AND CONTROLS NESTED IN AN AMBISPECTIVE COHORT TO EVALUATE THE EFFECT OF CO-MEDICATION ON THE EVOLUTION OF SARS-CoV-2 CORONAVIRUS INFECTION (COVID-19) (HULP-COVID19-ACE2-20)

DARWIN EU® study

No

Study countries

Spain

Study description

There is evidence that SARS-CoV-2 binds to the cellular ACE2 receptor to inoculate itself, which calls into question the use of drugs that may have an impact on the renin-angiotensin-aldosterone axis by increasing the probability of acquiring the infection. Most of the works maintain that it can favor the virus entering the body, although there is much controversy with the withdrawal or maintenance of drugs that intervene or collaterally affect this axis, since there are authors who argue that SARS-CoV -1 down-regulates ACE2 and increasingly ACE, and this can damage lung tissue, favoring the appearance of SARS. This can carry over to SARS-CoV-2 because of its genetic similarity to the former. Therefore, it is necessary to know whether withdrawal or maintenance or certain medication or vaccines are risk factors or increase the probability of a good evolution. For this last reason, we propose the present study.

Study status

Planned
Research institutions and networks

Institutions

Hospital La Paz
First published:
01/02/2024
Institution
School of Medicine
H. UL la Princesa Madrid, Spain

Contact details

Elena Ramirez

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

Own funding
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable